- Correction
- Open access
- Published:
Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis
BMC Cancer volume 24, Article number: 205 (2024)
The Original Article was published on 02 January 2024
Correction: BMC Cancer 24, 21 (2024)
Following publication of the original article [1], the authors reported an error in the fourth sentence of the first paragraph of the “Safety” sub-section of the “Results” section (copied and in bold below for your ease of reference): The proportion of drug discontinuation caused by TEAEs in the three treatment groups of SERENA-2 was 14.9% (camizestrant 75 mg), 21.9% (camizestrant 150 mg), and 4.1% (standard-of-care ET), respectively. We have quoted the proportion of TEAEs leading to dose interruption, rather than those leading to discontinuation which is an error. The correct sentence should be: The proportion of drug discontinuation caused by treatment related AEs (TRAEs) in the three treatment groups of SERENA-2 was 2.7% (camizestrant 75 mg), 0% (camizestrant 150 mg), and 0% (fulvestrant as standard-of-care ET), respectively.
The original article [1] has been corrected.
References
Huang X, Yu Y, Luo S, et al. The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis. BMC Cancer. 2024;24:21. https://doi.org/10.1186/s12885-023-11722-4.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s12885-023-11722-4.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Huang, X., Yu, Y., Luo, S. et al. Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis. BMC Cancer 24, 205 (2024). https://doi.org/10.1186/s12885-024-11932-4
Published:
DOI: https://doi.org/10.1186/s12885-024-11932-4